Physician profile
Laura Hendricks
NPI 1982047148
$862.32
in general payments reported to CMS, 2019-2025
13 companies · $41.50 in 2025
The $41.50 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.29 · 2020: $54.51 · 2021: $214 · 2022: $97.16 · 2023: $264 · 2024: $105 · 2025: $41.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $201.60 | 2019-2024 | |
| Glaxosmithkline, LLC. | $174.99 | 2020-2024 | Bexsero |
| Kaleo, INC. | $113.57 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $98.66 | 2020-2024 | Vaxelis, Gardasil 9, Rotateq |
| Corium, LLC | $48.15 | 2023 | Azstarys |
| Organon LLC | $43.39 | 2023-2024 | Nexplanon |
| Sanofi-Aventis U.S. LLC | $41.50 | 2025 | |
| Ironshore Pharmaceuticals INC. | $37.37 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.81 | 2020-2021 | |
| Seqirus USA INC | $26.90 | 2021-2023 | Flucelvax Quadrivalent |
| Vertical Pharmaceuticals, LLC | $17.38 | 2019 | |
| Pfizer INC. | $14.49 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.51 | 2023 | Flumist Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Hendricks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.